PATIENT REPORTED OUTCOMES IN THE DIAGNOSIS AND TREATMENT OF LYMPHOMA
Dr Elizabeth Goodall,
Haematologist and PhD student
Austin Health, Olivia Newton-John Cancer Research Institute & Monash Health, Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne | February 2025
Dr. Elizabeth Goodall (BMedSci Hons, MBBS Hons, FRACP, FRCPA) is a PhD student and early career researcher with La Trobe University and the Olivia Newton John Cancer Research Institute (ONJCRI), and Haematologist at Austin Health and Monash Health, Melbourne.
After completing her undergraduate degree in Medical Sciences at La Trobe University she went onto complete an Honours degree in malaria research before enrolling in Medicine at Monash University, Gippsland, Victoria in Australia.
Following medical school, she trained at Austin Health and successfully completed both clinical and laboratory haematology programs before moving to a lymphoma clinical trials fellowship at Monash Health. This fellowship provided essential clinical skills and has fostered a life-long interest in improving patient access to trials, finding ways to better select therapies for patients with blood cancers and learning more about the patient’s experience throughout treatment.
Her specific interest in how patients experience their illness and treatment forms the basis for her research in improving patient outcomes. This research comes at a pivotal time in modern lymphoma management with an ever-increasing number of treatment options available and renewed focus on each patient’s journey.
This has led to her PhD on Patient Reported Outcomes (PROs) which will focus on the accurate documentation of the patient experience and learn how best to include this data for future clinical trial design, an essential component of obtaining excellent treatment outcomes. For this work she is the 2025 recipient of the Haematology Society of Australia and New Zealand and the Leukaemia Foundation New Investigator PhD Scholarship which will provide invaluable support throughout the PhD.
-
Superslayer taking on antibiotic-resistant bacteria
Dr Katharina Richter is a visionary leader in MedTech, acclaimed for innovation and gender diversity. With over 40 awards to her name, including MIT Innovator Under 35 Asia-Pacific, and Prime Minister’s Prize for New Innovator finalist, she has shattered barriers as an entrepreneur, scientist, and ‘superbug slayer.’ Katharina’s groundbreaking work in combating antibiotic-resistant bacteria has resulted in 6 innovative treatments, 3 of which are patented, offering hope against deadly infections.
-
Next Generation Condom Contraception, Dr Simon Cook
Dr. Simon Cook, Co-Founder and Executive Director of Operations at Eudaemon Technologies, has had a diverse and impactful career journey. Beginning with a background in biotechnology from the University of Wollongong, his focus on bacterial pathogenesis during his PhD led him to study Group A Strep and the streptokinase protein.
Subsequently, Dr. Cook ventured into a unique project funded by the Bill and Melinda Gates Foundation, where he became involved in the development of a next-generation condom to address existing issues such as feel, odour, and taste.
-
Respiratory health and the microbiome in the lung environment
Dr Taylor leads the Respiratory Health Group within the Microbiome and Host Health Program. His research employs tailored techniques that allow the lung environment to be characterised to a high level of accuracy, including detailed measurements of airway microbiology (microbiome), mucus composition, and inflammation. This information is used to identify predictive markers of chronic lung disease severity as well as determine effective forms of therapy.
